- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Impedimed Ltd (IPD)
Impedimed Ltd stock price live, this page displays ASX IPD stock exchange data. View the IPD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Impedimed Ltd real time stock price chart below.
What Is the Impedimed Ltd Stock Price Today?
The Impedimed Ltd stock price today is 0.003.
What Is the Stock Symbol for Impedimed Ltd?
The stock symbol for Impedimed Ltd is "IPD."
What Stock Exchange Does Impedimed Ltd Trade On?
Impedimed Ltd is listed and trades on the Sydney stock exchange.
Is Impedimed Ltd a Good Stock to Buy?
Determining whether Impedimed Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPD quote. (ISIN: AU000000IPD8)
What Is the Impedimed Ltd Stock Price Today?
The Impedimed Ltd stock price today is 0.003.
What Is the Stock Symbol for Impedimed Ltd?
The stock symbol for Impedimed Ltd is "IPD."
What Stock Exchange Does Impedimed Ltd Trade On?
Impedimed Ltd is listed and trades on the Sydney stock exchange.
Is Impedimed Ltd a Good Stock to Buy?
Determining whether Impedimed Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPD quote. (ISIN: AU000000IPD8)
Sydney
Currency in AUD
0.003
-0.001(-25.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.003
0.005
52 wk Range
0.003
0.041
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0030.005
52 wk Range
0.0030.041
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IPD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
0.020
Upside
+555.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Impedimed Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Impedimed Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 0.020
(+555.33% Upside)
Impedimed Ltd Earnings Call Summary for Q1/2027
- Operating cash outflow improved to AUD 2.5M from AUD 4.9M, but total contract value fell 20% to AUD 4.4M as U.S. unit sales dropped 22% to 28 units.
- CEO Johnson called Q1 sales performance 'not acceptable,' citing execution problems and weak account control requiring commercial team restructuring.
- Average renewal pricing rose 18% despite volume weakness; company maintains 87% gross margin but cash runway stands at just 4.7 quarters.
- New NAPBC lymphedema standard creates opportunity across 540 accredited centers with Jan 2028 compliance deadline; current penetration only 25%.
- FDA clearance for sarcopenia assessment expands platform beyond lymphedema; no formal guidance provided as management focuses on rebuilding sales execution.
Last Updated: 2026-10-29, 06:42 p/m
Read Full TranscriptEarnings
Latest Release
Aug 27, 2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
7.1M / 4.4M
Compare IPD to Peers and Sector
Metrics to compare | IPD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −1.3x | −0.2x | |
PEG Ratio | 0.31 | −0.37 | 0.00 | |
Price/Book | 1.1x | 4.3x | 2.6x | |
Price / LTM Sales | 0.8x | 3.6x | 2.8x | |
Upside (Analyst Target) | - | 67.2% | 65.6% | |
Fair Value Upside | Unlock | 10.0% | 10.0% | Unlock |
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Impedimed (IPD) Stock Price Today?
The Impedimed stock price today is 0.003 AUD.
What Stock Exchange Does Impedimed Trade On?
Impedimed is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Impedimed?
The stock symbol for Impedimed is "IPD."
What Is the Impedimed Market Cap?
As of today, Impedimed market cap is 10.990M AUD.
What Is Impedimed's Earnings Per Share (TTM)?
The Impedimed EPS (TTM) is -0.012.
When Is the Next Impedimed Earnings Date?
Impedimed will release its next earnings report on Nov 09, 2026.
From a Technical Analysis Perspective, Is IPD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Impedimed Stock Split?
Impedimed has split 6 times.
How Many Employees Does Impedimed Have?
Impedimed has 66 employees.
What is the current trading status of Impedimed (IPD)?
As of Nov 07, 2026, Impedimed (IPD) is trading at a price of 0.003 AUD, with a previous close of 0.004 AUD. The stock has fluctuated within a day range of 0.003 AUD to 0.005 AUD, while its 52-week range spans from 0.003 AUD to 0.041 AUD.
What Is Impedimed (IPD) Price Target According to Analysts?
The average 12-month price target for Impedimed is 0.020 AUD, with a high estimate of 0.04 AUD and a low estimate of 0.00863 AUD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +555.33% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.